Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability
Phase 2, Randomized, Double-blind, Placebo-controlled Study (Part A) Followed by a Phase 3, Randomized, Double-blind, Placebo Controlled Study (Part B) With an Open Label Extension (Part C) and Long-term Extension (Part D) to Evaluate the Efficacy, Safety and Tolerability of Rilzabrutinib in Adult Participants With Inflammatory Common Variable Immunodeficiency (iCVID)
This is a 4-part study where both Part A and Part B, which starts after the completion of Part A, are randomized (2:1), double-blinded, placebo-controlled studies, followed by an open label (Part C) and long-term extension period (Part D), phase 2 and 3 study, designed to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of rilzabrutinib in adult patients with iCVID.
In Part A, all participants will have iCVID associated ILD and at least one additional inflammatory/ autoimmune complication (cytopenia [thrombocytopenia, anemia] and/or lymphoproliferative disease [splenomegaly, lymphoid hyperplasia]). At the completion of 24 weeks in Part A, participants will be assessed to the predefined No Response Citeria and may elect to discontinue the DB period (Part A) and enter the OL period (Part C).
Alternatively, for Part B, all participants will have CVID associated with at least one of the following: ILD, other inflammatory/ autoimmune complications (cytopenia, lymphoproliferative disease).
Part A: 32-week DB treatment of rilzabrutinib or placebo. Part B: 32-week DB treatment of rilzabrutinib or placebo. Part C: 32-week OL treatment of rilzabrutinib. Part D: OL treatment of rilzabrutinib until the last-patient-in (LPI- Part D) completes 52 weeks of treatment.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名：Trial Transparency email recommended (Toll free for US & Canada)
- 电话号码：option 6 800-633-1610
- 邮箱：Contact-US@sanofi.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria
- Participants who have previously been diagnosed with CVID based on the following criteria A) Documented low serum IgG compared to age-adjusted reference ranges B) Documented low IgA and/or IgM compared to age-adjusted reference range C) Immunophenotypic findings consistent with CVID D) Absence of any other defined immunodeficiency state
- Receiving immunoglobulin IV or SC replacement therapy
- Participants who have been diagnosed with one or more of the following inflammatory complications (iCVID) A) Interstitial lung disease (ILD) B) CVID-related cytopenia for >3 months since diagnosis - thrombocytopenia or anemia C) Lymphoproliferative disease on historical CT imaging - splenomegaly or lymphoid hyperplasia
- Eastern Cooperative Oncology Group performance status Grade 2 or lower, at screening
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
Exclusion criteria
- Active pulmonary infection at screening that could account for the HRCT abnormalities
- Clinically significant medical history or ongoing chronic illness that would jeopardize the safety of the participant or compromise the quality of the data derived from his or her participation in the study as determined by the Investigator (e.g. hepatobiliary conditions causing hepatic impairment)
- Refractory nausea or vomiting
- Chronic uncontrolled infectious diseases as determined by the Investigator
- Laboratory abnormalities at the screening visit (e.g. elevated liver enzymes)
- Recent history of substance, alcohol abuse or mental illness
- Malabsorption syndromes, active moderate-to-severe enteropathy
- Concurrent treatment with immunosuppressive or immunomodulatory drugs other than corticosteroids The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较：placebo
placebo |
Oral tablet |
|
实验性的：rilzabrutinib
rilzabrutinib |
Oral tablet |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of participants with iCVID who meet any responder definitions
大体时间：At Week 32
|
In participants with ILD at baseline, a responder is defined as achieving a clinically meaningful response at Week 32. In participants with cytopenia (thrombocytopenia, anemia) at baseline, a responder is defined as achieving therapeutic efficacy at Week 32, defined as Durable platelet response or Durable hemoglobin response (DHR) between W16 and W32, and no rescue medication for thrombocytopenia is taken at any time. In participants with lymphoproliferative disease (splenomegaly or lymphoid hyperplasia) at baseline, a responder is defined as achieving therapeutic efficacy by Week 32. |
At Week 32
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in FACIT-Fatigue total score at Week 24 in Part A and Week 32 in Part B
大体时间：At Week 24 in Part A and Week 32 in Part B
|
At Week 24 in Part A and Week 32 in Part B
|
|
|
Percent change from baseline in FVC% predicted at Week 32
大体时间：At Week 32
|
At Week 32
|
|
|
Percent change from baseline in diffusing capacity of the lung for carbon monoxide at Week 32
大体时间：At Week 32
|
At Week 32
|
|
|
Change from baseline in FACIT-dyspnea severity score at Week 24 in Part A and Week 32 in Part B
大体时间：At Week 24 in Part A and Week 32 in Part B
|
At Week 24 in Part A and Week 32 in Part B
|
|
|
Change from baseline in time spend in moderate to vigorous physical activity measured with a wearable device
大体时间：At Week 32
|
At Week 32
|
|
|
Incidence of treatment-emergent adverse events (TEAE), serious AEs (SAE), TEAE leading to permanent discontinuation, adverse events of special interest (AESI)
大体时间：Until Week 116 of LPI for Part D
|
including clinical laboratory evaluations, vital sign measurements, and electrocardiograms |
Until Week 116 of LPI for Part D
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- EFC20516
- 2026-525354-10 (注册表标识符：CTIS)
- U1111-1325-2663 (注册表标识符：WHO UTN)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.